Result of AGM

Summary by AI BETAClose X

Scancell Holdings PLC announced that all resolutions proposed at the Annual General Meeting held on October 30, 2025, were duly passed. The company is focused on developing targeted off-the-shelf active immunotherapies. Their lead product from the DNA ImmunoBody platform, iSCIB1+, has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy and additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the lead peptide immunotherapy from their Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. Additionally, GlyMab Therapeutics Ltd., a wholly-owned subsidiary, has an early-stage pipeline of GlyMab antibodies, two of which have been licensed and are being developed by Genmab A/S.

Disclaimer*

UK 100

Latest directors dealings